Bempedoic acid (ETC-1002),also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an
Introduction: Non-statin therapies may improve long-term outcomes in patients with atherosclerotic cardiovascular disease (ASCVD) who experience statin-associated side effects (SASE). Objective: To examine the cost-effectiveness of a newly approved combination of bempedoic acid and ezetimibe (BAEze) in...
bempedoic acid. The healthcare systems in the area are progressively incorporating novel treatments, in harmony with health policies that support population health and the management of chronic illnesses. As the prevalence of dyslipidemia rises, nations like France, Germany, and the UK show a strong...
725 Cost Effectiveness of Bempedoic Acid for Those at High Risk Cardiovascular Diseasedoi:10.1016/j.hlc.2020.09.732K. PereraN. KamZ. AdemiD. LiewE. ZomerHeart, Lung and Circulation
Bempedoic acidCost-effectivenessCardiovascular diseaseLipid-loweringPreventionBACKGROUND: Bempedoic acid is a novel adenosine triphosphate citrate lyase inhibitor shown to reduce low density lipoprotein cholesterol when used as an adjunct lipid-lowering therapy in patients with high cardiovascular disease (CVD)...
As a result the need for PCSK9 inhibitors (PCSK9i) is projected to increase significantly, with a concomitant substantial impact on treatment cost. Adding the novel lipid lowering agent bempedoic acid (BA) to established oral lipid lowering therapy could provide an affordable alternative to PCSK9...
Unfortunately, some of these strategies remain expensive, such as the use of proprotein convertase subtilisin/kexin type 9 inhibitors, thus new agents with more affordable cost/effectiveness ratio are welcome. Bempedoic acid is an interesting new opportunity to manage the complex scenario of ...